Pathogenesis of joint destruction
Although a specific antigen that triggers off the immune response in RA has not been convincingly identified, cellmediated immune responses (especially from the T cells) have been shown to be responsible for RA joint inflammation. In an susceptible host (e.g. a person with the appropriate genetic background), the T cell response results in the elaboration of T cell cytokines, with resultant recruitment of inflammatory cells, including neutrophils, macrophages, B cells and memory T cells. A target of the inflammatory cells is the synovium which becomes markedly hyperplastic and infiltrated with mononuclearcells. One feature of RA that distinguishes it from other inflammatory arthropathies is the propensity for the synovium to become locally invasive at the synovial interface with cartilage and bone. This destructive mass is called "pannus" and is responsible for the characteristic marginal erosions observed in RA [5] . Cartilage is further destroyed in RA by the catabolic effects of cytokines such as IL-1, IL-6 and tumour necrosis factor-alpha (TNF-α) and the production of metalloproteinases, which can degrade extra-cellular matrix/cartilage, causing more joint damage [5] .
Apart from synovitis, inflammation of the adjacent intertrabecular space (osteitis) also correlates with the development of radiographic bone erosions.Articular bone erosion represents localized bone loss (osteolysis), which results from an imbalance in which bone resorption by osteoclasts is favoured over bone formation by osteoblasts [6] . In RA, TNF-α and receptor activated nuclear factor ligand (RANKL) are key cytokines mediating the activation of the osteoclasts [7] .
Studies have shown that erosive disease develops early in the course of RA in the majority of patients. The rate of progression is fastest in the first 2 years [8] . Longitudinal studies have shown that after 2 years approximately 36% of patients have erosions, 47% by 5 years [9] and 63% by 8 years [10] . If both joint space narrowing and erosions are considered, up to 70% of patients will show radiographic damage after 3 years [11] . pain and swelling, improving function and reducing the ESR. However, its efficacy at inducing disease remission is limited (only in approximately 25% of patients) andhence less efficacious at reducing radiographic progression [13] . Biologics are monoclonal antibodies produced against various inflammatory cytokines such as TNF-α or IL-6. Compared to MTX, biologics are very much more effective atinducing disease remission and hence reducing the progression of joint damage as assessed by radiographic change scores (e.g. [13] [14] [15] . Unfortunately, a major barrier to the widespread use of biologics is their high cost. In addition, approximately 20% of patients do not achieve adequate disease suppression with biologic treatment [16] . So, despite the availability of treatment, many patients with RA remain undertreatedand thus have continuing joint destruction. Nonetheless, since the mid-1990s, studies have shown that the amount of hand surgery in RA patients has been slowly declining, postulated to improvements in medical therapy [17, 18] .
Conclusion
Adequate and early treatmentof RA does reduce the rate of radiographic progression and hence joint damage. Although the drugs are available, the most effective drugs are not widely used due to cost issues. Thus, RA hand surgery will still be needed in the foreseeable future.
